-
Auris Medical Holding AG (NASDAQ: EARS) shares
touched a new 52-week low of $2.15 as the company issued results from TACTT2 trial with Keyzilen in acute inner ear tinnitus.
The trial did not meet co-primary efficacy endpoints. The company also reported Q2 earnings of CHF0.25 per share.
-
Cerulean Pharma Inc (NASDAQ: CERU) shares touched
a new 52-week low of $1 on failed CRLX101/Avastin trial results. Leerink Swann, Janney Capital and JMP Securities downgraded
the stock following the news.
-
DryShips Inc. (NASDAQ: DRYS) shares dropped 8.1
percent to touch a new 52-week low of $0.960. DryShips shares have tumbled 96.93 percent over the past 52 weeks, while the
S&P 500 index has gained 4.07 percent in the same period.
-
Bottomline Technologies (NASDAQ: EPAY) shares
reached a new 52-week low of $20.20. Bottomline Technologies shares have declined 23.14 percent over the past 52 weeks, while
the S&P 500 index has gained 4.07 percent in the same period.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.